ClinicalTrials.Veeva

Menu

Elucidating Age-related Comorbidity Patterns in Down Syndrome (DS) (GO-DS21)

K

King's College London

Status

Completed

Conditions

Down Syndrome

Treatments

Other: No interventions - observational study

Study type

Observational

Funder types

Other

Identifiers

NCT05310552
GODS21CS

Details and patient eligibility

About

This study is a non-drug, multicenter, prospective cohort study. It will be conducted in 300 volunteers from 12 to 45 years of age (inclusive) with a diagnosis of Down syndrome from 3 countries (France, Spain, United Kingdom (UK)). The basic hypotheses of the study are the following:

  1. Diseases (and comorbidity) arise from one or more biological networks perturbed by the genetic disorder (trisomy 21) through interaction with environmental risks factors and epigenetic changes.
  2. Health comorbidity patterns in DS individuals (particularly of obesity and related conditions) will likely vary by age and sex.
  3. Obesity comorbidity patterns will relate to variation in factors including lifestyle, stress-response, severity of intellectual disability (ID) and variation in cognitive domains such as executive functioning.
  4. Stress responses, as measured with cortisol concentrations, will differentiate individuals with DS who are obese and those who are not. Extremes in phenotype (Obese vs. Non-obese) will be related to differences in the metabolomic, transcriptomic, and microbiome concentrations.

Full description

The study will be conducted in n= 300 volunteers with DS from 3 countries (France, Spain, UK); equal numbers in 3 age groups (12 - 18 years; 19 - 34 years; 35 - 45 years). The total number of volunteers expected to be included in each country is n = 100.

From the initial cross-sectional cohort, individuals will be selected on the basis of obesity status and invited to participate in a nested case-control study (n = 30 for normal weight DS individuals and n = 30 DS individuals with extreme phenotype). In adults, normal weight is defined as BMI 18.5 to 24.9 and significant obesity as BMI > 35 kg/m2. In children under age 18, the research team will use the International Obesity Task Force (IOTF) curves which are international norms) with IOTF > 30 for obese and IOTF 18.5 - 25 for the normal weight group. The research team will monitor allocation using monthly eCRF recruitment reports for central allocation of recruits to ensure balance between age, sex and BMI between the "cases" and the "controls".

Enrollment

230 patients

Sex

All

Ages

12 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females aged 12 to 45 years
  • With established genetic diagnosis of Down syndrome (full trisomy 21; based on karyotype results - not exclusion if not available but will need to confirm karyotype if not done previously)
  • Availability of parent/caregiver to accompany the subject to clinical visits and to be willing to give written informed consent, when necessary

Exclusion criteria

  • Confirmed mosaic trisomy 21, partial trisomy 21, or translocation
  • Comorbid conditions - Participation is allowed as long as the condition(s) are considered stable and it do not interfere with the participation of the study
  • Subjects with evidence of dementia or meeting clinical diagnoses for dementia
  • Participation in a medication treatment trial in the last 3 months prior to the study

Trial contacts and locations

3

Loading...

Central trial contact

Andre Strydom, Prof.; Miren Tamayo-Elizalde, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems